Acute myeloid leukemia (AML) is a clonal hematopoietic disorder that develops as a result of cumulative genetic and epigenetic events that affect key regulatory genes conferring a proliferative growth and survival advantage. Both intrinsic and acquired chemotherapeutic resistance remain as major limitations in the successful treatment of AML. 1 Evidence suggest that drug resistance mechanisms other than multidrug resistance phenotype are involved, such as reduced intracellular concentrations of ara-CTP, the active triphosphorylated form of Ara-C. However, Ara-C resistance-related changes in AML cells have not been well investigated using a genome-wide approach. Murine leukemia cell lines provide a readily available and more uniform disease platform for analysis of gene expression.
Comparison of gene expression patterns between Ara-Csensitive and -resistant cell lines should provide a valuable insight into the development of chemotherapy resistance. We have generated Ara-C-resistant murine leukemia cell lines, B117H and B140H, from their Ara-C-sensitive parental cell lines, B117P and B140P, respectively. 2, 3 To characterize the sensitive and resistant lines, their chromosomal features were examined using spectral karyotyping analysis as described previously. 4 It is known that cell lines tend to manifest chromosomal abnormalities, especially after an extensive passaging process. As expected, both Ara-C-sensitive and -resistant cells show multiple chromosomal alterations, including chromosome loss, translocation and amplification (data not shown). Consistent with our previous observation on proviral integration patterns, the resistant cells represent a cytogenetic feature related to parental cells. In addition, new chromosomal changes were also found in resistant cells (data not shown), suggesting that multiple clonal, extensive chromosomal aberrations occur after exposure to increasing doses of Ara-C. Table 1 Genes changed in expression level in the Ara-C-resistant cell lines and their gene ranking as determined by ANOVA support vector machine
Gene name
Affymetrix probe set ID Gene description n-fold Gene expression profiling was performed using Affymetrix 430A GeneChips under standard conditions in an Affymetrix fluidics station. GeneChips hybridization data were collected, corrected and statistically analyzed using programs including Statistical Analysis of Microarray, GeneData Analyst, Principal Components Analysis and Cluster. These experiments were repeated three times using three independently derived RNA probes for each cell line being evaluated. The microarray data were found to be highly reproducible and comparable between duplicate samples (data not shown). The raw data are available online at http://www.ncbi.nlm.nih.gov/geo/ (accession number GSE2788). A list of 929 genes with t-test (Po0.001) and fold change (X2.0) analysis was obtained, including 414 upregulated and 138 downregulated known genes in Ara-C-resistant cells. Expression changes for several genes were confirmed by quantitative real-time PCR analysis using the Light Cycler. Our microarray study has demonstrated that oligonucleotide microarray analysis can be used to clearly distinguish Ara-C-resistant and Ara-C-sensitive murine leukemia cell lines. We also provide a list of interesting and important genes that will need further functional analysis in vitro and in vivo (Table 1) .
Apoptosis plays an important role in the sequence of events during which anticancer drugs induce an antitumor response. Bcl2 and Bcl2l1 were both overexpressed in Ara-C-resistant cell lines. Constitutive overexpression of Bcl-2 or unchanged expression after treatment with chemotherapy is thought to confer drug resistance in hematologic malignancies. The downregulation of Bcl-2 protein by the antisense Bcl-2 oligonucleotide (Oblimersen sodium) may be a useful method for targeting the antiapoptotic protein and increase the effect of chemotherapeutic drugs. To test whether overexpression of Bcl2l1 can affect Ara-C response, pMIGR-Bcl-xL was constructed and used to produce VSV-G psudotyped retroviruses expressing Bcl2l1 and enhanced green fluorescent protein (EGFP) via an internal ribosome entry site-mediated cotranslation. pMIGR-Cda, expressing cytidine deaminase (Cda), the key Ara-C-inactivating enzyme, was also made and used as a positive control for cellular response to Ara-C in toxicological assays. Bcl2l1-or Cda-overexpressing B117p and B140p were then established through transduction of cell lines with these retroviruses followed by sorting for EGFP-positive cells using flow cytometry, as demonstrated by Western blotting assay using the antibody His-probe (Figure 1b) . The MTS tetrazolium assay was then used to determine cytotoxic response of AML cell lines, as described before. 3 As shown in Figure 1c , overexpression of Bcl2l1 in AML cell lines increased Ara-C resistance to different extents in different lines. Overexpression of Cda also increased Ara-C resistance, but to a lesser extent than Bcl2l1. These data indicate that Bcl2l1 and Cda can increase cellular resistance to Ara-C in a cell-dependent manner. In addition, Bcl2l1 contributed to drug resistance to a greater extent than Cda, providing a clue that cell apoptosis blockage may affect drug resistance more profoundly than drug intracellular inactivation.
DNA repair genes were also important components of the Ara-C-resistant cell line signature. Xrcc5 was significantly underexpressed in cells exhibiting Ara-C resistance. Xrcc5 has been shown to mediate repair of double-strand breaks via nonhomologous end joining (NHEJ). Our data also showed decreased expression of the mismatch repair (MMR) genes Msh2 and Msh6. The MMR system functions to correct replicative mismatches that escape DNA polymerase proofreading. Defective MMR results in an elevated rate of spontaneous mutations and was first identified in hereditary nonpolyposis colorectal cancer. MSI is generally detected in less than 10% of AML; however, a correlation between MSI and therapy-related AML has been found. Several recent studies have also implicated mutations in mismatch repair genes in Letters to the Editor chemotherapy resistance. 5 Our data suggest that loss of Msh2 and Msh6 may indeed play a role in the development of chemotherapy-resistant AML.
Factors that alter the metabolism and catabolism of Ara-C may induce chemoresistance in AML patients. Deoxycytidine kinase (dCK) is the key enzyme in the series of phosphorylating steps necessary to metabolize Ara-C to its pharmacologically active form, Ara-C triphosphate. Also, monophosphate forms of Ara-C are substrates for 5 0 nucleotidase (5NT) enzymes. 1 Galmarini et al. demonstrated that patients with a higher 5NT to dCK ratio had significantly shorter disease-free survival and overall survival. Our microarray data did not show any significant change in Dck expression level, but did show significant overexpression of two isoforms of the enzyme 5 0 nucleotidase, Nt5e (36-fold) and Nt5c2 (threefold), in Ara-C-resistant cells, consistent with a role in chemotherapy resistance.
One of the most dramatically upregulated genes revealed in our microarray data was amyloid beta (A4) precursor protein (App). APP encodes a glycoprotein of unknown function previously implicated in Alzheimer's disease and activation of monocytic lineage cells. Interestingly, APP was found to be the most overexpressed gene in AML with complex karyotypes and abnormal chromosome 21, compared to AML with normal cytogenetics. High APP expression also occurred in a subset of AML patients with normal cytogenetics. 5 To study the known biological interactions between the genes identified in the murine study, the SAM-generated 1520 genes were analyzed using the Ingenuity Pathway Analysis tool. A total of 1220 genes were mapped to genetic networks defined by the software. A total of 30 networks were identified as significant with a score of 3 or higher (Table 2) . Furthermore, the 929 murine genes with a P-value o0.001 and a twofold or greater expression change were compared with prognostically important genes identified in eight independent studies of AML patients using SAS programs specifically created for this purpose. 6, 7 Twenty-four genes that were identified as being prognostically important in human studies were found within the list of 929 murine genes, and led to the identification of two statistically significant genetic networks (Table 2) . These networks were most significantly associated with apoptosis, cell death, repair, proliferation, differentiation and survival, indicating that a number of novel genes may play a key role in Ara-C resistance. Of note, sorcin (Sri), a transporter that experienced a remarkable increase in the murine gene expression analysis, was identified as a significant prognosticator of patient outcome. RNA interference of SRI in drug-resistant K562 cells resulted in an increase in drug sensitivity, supporting the idea that SRI may be one of the transporters directly involved in the drug resistance mechanism. 8 Consistently, an increase in lysosomal activity was also reported in a daunorubicin-resistant AML cell line of HL-60, likely resulting in the sequestration of anticancer drugs away from their molecular targets. These data suggest that there is a partial overlap in the discovery of altered gene expression between our microarray study and the human studies, and that the commonly changed genes may be of high value for further examination for their effect on drug resistance.
This study provides a proof of principle for identifying candidate genes that influence Ara-C sensitivity. The genes and genetic pathways that we have identified provide a rationale for future functional studies and for novel therapies aimed at chemotherapy for refractory AML. There are currently no known specific biomarkers to indicate resistance to chemotherapy or to stratify treatment of chemotherapy-resistant disease. This information could be used to identify a signature of relapsed disease and to predict those who would be unlikely to benefit from treatment with Ara-C alone. It will be important to perform similar studies in humans by comparing gene expression signatures obtained at the time of AML diagnosis, with those obtained at relapse. The ultimate goal is to translate this molecular knowledge into improved patient survival, an aim we have yet to achieve. Table 2 Ingenuity Systems genetic networks affected by Ara-C resistance The JAK2 1849G4T mutation results in valine to phenylalanine substitute at 617 amino acid (JAK2 V617F ), and this molecular change occurs in most patients with polycythemia vera (PV) and in approximately 50% of patients with essential thrombocythemia (ET) or chronic idiopathic myelofibrosis (CIMF). [1] [2] [3] [4] Mitotic recombination at the terminal portion of the 9p region is considered to produce homozygous JAK2 V617F , and approximately 20-30% of PV patients have homozygous JAK2 V617F whereas most ET patients have heterozygous JAK2
V617F3 . However, it is still controversial whether JAK2 V617F is a primary genetic event in CMPD, and the frequency of homozygous JAK2 V617F varied in different reports, probably owing to technical differences or diagnostic criteria. 5 To clarify the biological and clinical features in JAK2 V617F -positive cells in CMPD, we attempted to measure the proportion of mutated alleles of JAK2 semiquantatively by the sequence-specific primer-single molecule fluorescence detection (SSP-SMPD) assay. 6 We studied JAK2 V617F in 211 individuals, including 103 patients with chronic myeloproliferative disorders (CMPD): 34 patients with PV, 51 with ET, nine with CIMF, five with chronic myeloid leukemia (CML) with myelofibrosis, one hypereosinophilic syndrome (HES) with myelofibrosis and three patients with unclassifiable CMPD. For the SSP-SMFD study, 10 ng of extracted DNA was amplified by the first-round polymerase chain reaction (PCR), and then extended by the fluorescencelabeled single nucleotide polymorphism (SNP)-specific primer. 6 To obtain reproducible results and to clarify the quantitative relationship between mutated allele and wild-type allele in the sample, we calculated the ratio of K2(T)/K2(G)% Â 100 (K2(T)/ K2(G)% ratio). 6 We mixed two reference plasmids with various ratios (percentages of mutation allele-specific oligonucleotide, that is, puc18_T: 0-100%), and we found that this method detects at least a 5% mixture of the T-specific population, that is, at least 10% of the population with heterozygous JAK2 V617F (data not shown). JAK2 V617F was detected in only three of the 85 patients with non-CMPD hematologic diseases, that is, three MDS with myelofibrosis ( Supplementary Information 1) . 6 All other normal subjects, cases of secondary erthrocytosis, acute and chronic leukemias, unclassified CMPD, HES and CMML had wild-type JAK2. Based on the new WHO criteria, 92.6% (25/27) of PV patients had JAK2 V617F with 18 heterozygous and seven homozygous JAK2 V617F . Two out of seven homozygous JAK2 V617F were judged as heterozygous JAK2 V617F by the PCR direct-sequence assay. All seven patients who did not meet the WHO criteria (non-WHO PV) had wild-type JAK2. Thirty-two of 51 ET patients (62.7%) had JAK2 V617F with 31 heterozygous and one homozygous JAK2
V617F by the SSP-SMFD: four ET patients judged as wild-type JAK2 by the PCR direct sequence were identified as heterozygous JAK2
V617F by the SSP-SMFD. Of the nine patients with CIMF, five had wild-type, three had heterozygous and one had homozygous JAK2
V617F
. This clearly indicates that the SSP-SMFD assay may be more sensitive for the detection of mutated alleles than the PCR direct sequence.
PV patients without JAK2 V617F (seven non-WHO PV plus two WHO-PV: all male) had a significantly lower leukocyte count, a lower platelet count and a lower frequency of palpable splenomegaly and requiring cytoreductive chemotherapy, when compared to PV patients with JAK2
V617F (Supplementary file 2) .
Recent work has revealed that at least some of the RNA samples, cell lines or data sets used to produce gene expression microarray results in our previous letter published in Leukemia 1 were likely switched. Because of the switch, we now have doubts about the list of genes initially described as differentially expressed in Ara-C-sensitive versus Ara-C-resistant cell lines (Tables 1, 2 and parts of the Discussion). We have therefore repeated the mRNA microarray analysis starting from new RNA samples and defined a different and shorter list of differentially expressed genes upon the acquisition of Ara-C resistance, which is published separately in this issue. 2 The cytogenetic analysis, shRNA transduction/Ara-C sensitivity assays, and the description of highly Ara-C-resistant derivative cell lines are all fully valid as presented in the letter of 2007. We, the authors, now wish to retract the original article published in 2007 by Yin et al. in Leukemia. 
